Background: The development of novel cannabis research methods that are compatible with current federal regulations is imperative to conduct studies of the effects of legal market cannabis. There is very little research on higher strength, higher Δ9-tetrahydrocannabinol (THC), which has become increasingly available since legalization. Research on strains containing cannabidiol (CBD), a second primary, but nonpsychotomimetic, cannabinoid, is very limited. Materials and Methods: Using a novel observational methodology, regular cannabis users were asked to use one of two legal market cannabis strains that they purchased from a local dispensary (one strain containing 8% THC and 16% CBD (THC+CBD) and one containing a 17% THC concentration, but no CBD (THC). After using their suggested cannabis strain as they typically would for a 3-day period, participants returned to the laboratory immediately after their final use. Measures included a blood draw to measure cannabinoid blood levels and circulating cytokines, self-reported subjective drug effects, and verbal recall memory. Results: Analysis of CBD/THC concentration levels in the blood following the 3-day strain manipulation suggests that all, but one participant (n=23/24) followed instructions and used their assigned strain. Individuals in the THC group (n=11) smoked no more than their usual amount, and participants who used the THC+CBD (n=12) strain smoked more than their reported usual amount, but did not have significantly different THC+metabolite blood levels from the THC group. The THC+CBD strain was also associated with less desire to smoke, lower levels of subjective drug effects, and lower levels of circulating cytokines (TNF-α, IL-6, and IL-1β) immediately after use. Conclusions: Initial results support the feasibility of this novel observational methodology involving brief manipulation of strain use. Preliminary findings indicate that participants may self-titrate cannabis use based on cannabinoid concentration and the THC+CBD strain was associated with lower levels of cannabis craving, subjective intoxication, and circulating cytokines.
Background: The development of novel cannabis research methods that are compatible with current federal regulations is imperative to conduct studies of the effects of legal market cannabis. There is very little research on higher strength, higher Δ9-tetrahydrocannabinol (THC), which has become increasingly available since legalization. Research on strains containing cannabidiol (CBD), a second primary, but nonpsychotomimetic, cannabinoid, is very limited. Materials and Methods: Using a novel observational methodology, regular cannabis users were asked to use one of two legal market cannabis strains that they purchased from a local dispensary (one strain containing 8% THC and 16% CBD (THC+CBD) and one containing a 17% THC concentration, but no CBD (THC). After using their suggested cannabis strain as they typically would for a 3-day period, participants returned to the laboratory immediately after their final use. Measures included a blood draw to measure cannabinoid blood levels and circulating cytokines, self-reported subjective drug effects, and verbal recall memory. Results: Analysis of CBD/THC concentration levels in the blood following the 3-day strain manipulation suggests that all, but one participant (n=23/24) followed instructions and used their assigned strain. Individuals in the THC group (n=11) smoked no more than their usual amount, and participants who used the THC+CBD (n=12) strain smoked more than their reported usual amount, but did not have significantly different THC+metabolite blood levels from the THC group. The THC+CBD strain was also associated with less desire to smoke, lower levels of subjective drug effects, and lower levels of circulating cytokines (TNF-α, IL-6, and IL-1β) immediately after use. Conclusions: Initial results support the feasibility of this novel observational methodology involving brief manipulation of strain use. Preliminary findings indicate that participants may self-titrate cannabis use based on cannabinoid concentration and the THC+CBD strain was associated with lower levels of cannabis craving, subjective intoxication, and circulating cytokines.
Authors: Jelena Klawitter; Cristina Sempio; Sophie Mörlein; Erik De Bloois; Jacek Klepacki; Thomas Henthorn; Maureen A Leehey; Edward J Hoffenberg; Kelly Knupp; George S Wang; Christian Hopfer; Greg Kinney; Russell Bowler; Nicholas Foreman; Jeffrey Galinkin; Uwe Christians; Jost Klawitter Journal: Ther Drug Monit Date: 2017-10 Impact factor: 3.681
Authors: Heather S McKay; Joseph B Margolick; Otoniel Martínez-Maza; Joseph Lopez; John Phair; Giovanna Rappocciolo; Thomas N Denny; Larry I Magpantay; Lisa P Jacobson; Jay H Bream Journal: Cytokine Date: 2016-12-09 Impact factor: 3.861
Authors: Sagnik Bhattacharyya; Paul D Morrison; Paolo Fusar-Poli; Rocio Martin-Santos; Stefan Borgwardt; Toby Winton-Brown; Chiara Nosarti; Colin M O' Carroll; Marc Seal; Paul Allen; Mitul A Mehta; James M Stone; Nigel Tunstall; Vincent Giampietro; Shitij Kapur; Robin M Murray; Antonio W Zuardi; José A Crippa; Zerrin Atakan; Philip K McGuire Journal: Neuropsychopharmacology Date: 2009-11-18 Impact factor: 7.853
Authors: Jane Metrik; Damaris J Rohsenow; Peter M Monti; John McGeary; Travis A R Cook; Harriet de Wit; Margaret Haney; Christopher W Kahler Journal: Exp Clin Psychopharmacol Date: 2009-08 Impact factor: 3.157
Authors: Jane Metrik; Christopher W Kahler; Brady Reynolds; John E McGeary; Peter M Monti; Margaret Haney; Harriet de Wit; Damaris J Rohsenow Journal: Psychopharmacology (Berl) Date: 2012-05-16 Impact factor: 4.530
Authors: L Cinnamon Bidwell; Jarrod M Ellingson; Hollis C Karoly; Sophie L YorkWilliams; Leah N Hitchcock; Brian L Tracy; Jost Klawitter; Cristina Sempio; Angela D Bryan; Kent E Hutchison Journal: JAMA Psychiatry Date: 2020-08-01 Impact factor: 21.596
Authors: L Cinnamon Bidwell; Hollis C Karoly; Marco Ortiz Torres; Ashley Master; Angela D Bryan; Kent E Hutchison Journal: Psychopharmacology (Berl) Date: 2021-10-27 Impact factor: 4.530
Authors: Laurel P Gibson; Hollis C Karoly; Jarrod M Ellingson; Jost Klawitter; Cristina Sempio; Julia E Squeri; Angela D Bryan; L Cinnamon Bidwell; Kent E Hutchison Journal: Addict Biol Date: 2021-08-31 Impact factor: 4.093
Authors: Hollis C Karoly; Michael A Milburn; Ashley Brooks-Russell; Mary Brown; Jessica Streufert; Angela D Bryan; Nicholas P Lovrich; William DeJong; L Cinnamon Bidwell Journal: Cannabis Cannabinoid Res Date: 2020-09-10
Authors: Martin Krsak; Nikolas I Wada; Michael W Plankey; Gregory L Kinney; Marta Epeldegui; Chukwuemeka N Okafor; Mackey Reuel Friedman; Frank J Palella; Kristine M Erlandson Journal: Cannabis Cannabinoid Res Date: 2021-04-15
Authors: Laurel P Gibson; Charleen J Gust; Jarrod M Ellingson; Sophie L YorkWilliams; Cristina Sempio; Jost Klawitter; Angela D Bryan; Kent E Hutchison; L Cinnamon Bidwell Journal: Drug Alcohol Depend Date: 2021-04-20 Impact factor: 4.852
Authors: Cristina Sempio; L Cinnamon Bidwell; Kent Hutchison; Marilyn A Huestis; Jost Klawitter; Uwe Christians; Thomas K Henthorn Journal: Ther Drug Monit Date: 2021-08-01 Impact factor: 3.118